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Abstract 
Background/Objective: Prognostication is a routine part of the delivery of neurocritical care for most patients with 
acute neurocritical illnesses. Numerous prognostic models exist for many different conditions. However, there are 
concerns about significant gaps in knowledge regarding optimal methods of prognostication.
Methods: As part of the Arbeitstagung NeuroIntensivMedizin meeting in February 2018 in Würzburg, Germany, a 
joint session on prognostication was held between the German NeuroIntensive Care Society and the Neurocritical 
Care Society. The purpose of this session was to provide presentations and open discussion regarding existing prog-
nostic models for eight common neurocritical care conditions (aneurysmal subarachnoid hemorrhage, intracerebral 
hemorrhage, acute ischemic stroke, traumatic brain injury, traumatic spinal cord injury, status epilepticus, Guillain–
Barré Syndrome, and global cerebral ischemia from cardiac arrest). The goal was to develop a qualitative gap analysis 
regarding prognostication that could help inform a future framework for clinical studies and guidelines.
Results: Prognostic models exist for all of the conditions presented. However, there are significant gaps in prognosti-
cation in each condition. Furthermore, several themes emerged that crossed across several or all diseases presented. 
Specifically, the self-fulfilling prophecy, lack of accounting for medical comorbidities, and absence of integration of 
in-hospital care parameters were identified as major gaps in most prognostic models.
Conclusions: Prognostication in neurocritical care is important, and current prognostic models are limited. This gap 
analysis provides a summary assessment of issues that could be addressed in future studies and evidence-based 
guidelines in order to improve the process of prognostication.
Keywords: Prognostication, Self-fulfilling prophecy, Outcome predictors, Comorbidities
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Introduction
The word prognostication derives from the ancient Greek 
word πρόγνωσις (προ [pro-; before] + γνώσις [gnosis; 
knowledge] or γιγνώσκειν [verb; come to know). Prog-
nostication involves an attempt to predict the future or, 
specifically in medicine, the course of a disease. Although 
no person can always predict the future with perfect 
accuracy, prognostic attempts for various diseases are 
based on empiric knowledge from the past. That is, how 
specific patient populations diagnosed with the disease 
in question fared over times. Of course this depends on 
the length of time and on the specific outcome of inter-
est. In medicine, length of follow-up extends either from 
symptom onset or hospital admission to discharge or 
few months or years later and specific outcomes range 
from mortality to cognitive or physical status (depend-
ence or independence). In neurocritical care, prognos-
tication takes on a high priority because many diseases 
are either fatal or lead to substantial disability. Patients, 
families, and healthcare providers want to know what to 
expect and these expectations often influence decisions 
regarding acute care and long-term support. Further-
more, prognostication is often considered in relation to 
a specific time point, but may be relevant across a con-
tinuum of outcomes and time points. Prognosis for early 
mortality and long-term functional independence may be 
important for different types of decisions such as whether 
to continue aggressive neurointensive care or whether 
arrangements should be made regarding job prospects 
and family financial planning. The plateau of functional 
status and the time course and trajectory to get there may 
be the most important prospect to patients and fami-
lies. However, most studies assess a formal outcome at 
an arbitrary snapshot in time such as hospital discharge, 
3 months, 6 months, or 1 year. Prognosis assessment can 
vary between different disease states and between avail-
able variables, scores, and scales defined by the literature.
In February 2018, the Arbeitstagung NeuroIntensiv-
Medizin (ANIM) meeting took place in Würzburg, Ger-
many, and involved substantial collaboration between the 
German Neurocritical Care Society (DGNI) and the Neu-
rocritical Care Society (NCS). Because of the recognized 
importance of prognostication in neurocritical care, this 
collaboration included a special joint session focusing on 
gaps in current prognostication paradigms and models in 
neurocritical care. The purpose of this session was to pro-
vide a forum for presentation and discussion regarding 
existing formal prediction models across eight different 
common neurocritical care conditions (aneurysmal suba-
rachnoid hemorrhage, intracerebral hemorrhage, acute 
ischemic stroke, traumatic brain injury, traumatic spinal 
cord injury, status epilepticus, Guillain–Barré Syndrome 
(GBS) and global cerebral ischemia from cardiac arrest). 
Members of DGNI and NCS who were recognized as 
experts in prognostication or clinical care of these con-
ditions (one expert per condition) were selected by the 
session organizing committee. They were instructed to 
undertake a general literature search regarding prognos-
tication models for their assigned condition, to present 
an oral 15 min-summary, and to moderate and integrate 
feedback from the audience into a brief written summary. 
Formal defined literature searches or systematic reviews 
with utilization of a librarian were not undertaken nor 
was there specific grading of the literature using an estab-
lished methodological approach. Rather, the intent was 
to provide an overview for discussion in order to identify 
gaps in current prognostication models as well as themes 
that might cross over between different conditions. Rec-
ognizing that prognostication paradigms involve broader 
aspects than just prognostication models, this focus was 
chosen specifically in order to frame the gap analysis and 
conform to available program time. This report involves a 
summary of the individual presentations which were syn-
thesized into this single document by the session mod-
erators. It is hoped that this gap analysis can provide a 
framework for DGNI and NCS members as well as the 
neurocritical care community worldwide to improve the 
study of prognostication tools and methods and guide-
lines for their use.
Subarachnoid Hemorrhage
Outcome Predictors and Prognostic Models
The long-term outcome after aneurysmal subarachnoid 
hemorrhage (SAH) has improved over the last decades 
[1–4]. The original grading scales of clinical severity, 
Hunt and Hess scale [5], and World Federations of Neu-
rosurgical Societies (WFNS) scale [6], are still the most 
widely used and remain the most important predictors of 
long-term poor functional outcome and mortality [7, 8]. 
In comparative research, there was no difference in the 
precision of outcome prediction between the Hunt and 
Hess grade and the WFNS using the modified Rankin 
scale (mRS) and the Glasgow Outcome scale (GOS) at 
discharge, 6 months and 12 months [9–11]. However, in 
the WFNS scale there was substantial overlap between 
grade II and III, III and IV with similar outcomes for the 
assigned grades [9, 12].
The original scales, Hunt and Hess and WFNS, were 
modified to enable more precise and reliable distinction 
between the grades. Most of them are based on the Glas-
gow Coma scale (GCS) [13]. The modified WFNS scale 
was better able to distinguish between grades I, II, and III 
as well as IV and V when predicting the mean GOS and 
mRS at 90  days [14]. Another GCS-based scale (“Prog-
nosis on Admission of Aneurysmal Subarachnoid Hem-
orrhage-PAASH scale”) clearly distinguished 6-month 
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outcome based on the GOS and mRS [15, 16]. The 
Revised GCS-based scale on four significant breakpoints 
of the admission GCS predicted long-term outcome 
(mRS at 3 and 12 months) better in poor grade patients 
compared to GCS, WFNS, and Hunt–Hess scales [17]. 
The Full Outline of UnResponsiveness (FOUR) score 
with four scoring items: eye opening, eye and eyelid 
movements (E), motor examination (M), brain stem 
reflexes (B), and respiratory patterns (R) were designed 
for more detailed assessment of the level of conscious-
ness [18]. The total, eye, motor, and respiratory FOUR 
scores obtained on day 0 and 7 after SAH were associ-
ated with mortality and functional outcome (mRS and 
GOS) at 1 and 6 months [19]. This score obtained on day 
14 was also associated with functional outcome (GOS) at 
6 months [19]. The SAH Physiologic Derangement score 
was designed to identify potentially reversible disorders 
during the acute phase of SAH. This score was found to 
be a better predictor of death and severe disability (mRS) 
at 3 months after SAH [20].
Few prognostic models were developed to predict long-
term outcome after SAH. Whereas the SAH score is 
based on patient’s age, admission GCS, and comorbidities 
[21]; the HAIR score [11, 22] composed of Hunt–Hess 
score, age, the presence of intraventricular hemorrhage, 
and rebleeding within 24  h; and the ABC score includ-
ing GCS, troponin I, and protein S-100ß [23] obtained on 
admission, focus on prediction of in-hospital, discharge, 
and long-term mortality. The two more recently devel-
oped models, the Functional Recovery Expected after 
Subarachnoid Hemorrhage (FRESH) score and the Suba-
rachnoid Hemorrhage International Trialists (SAHIT) 
score aim at prediction of long-term functional out-
come and are considered to be the most comprehensive 
[24–26].
The FRESH score (Table 1) is composed of Hunt–Hess 
grade, APACHE II physiologic subscore on admission, 
age, and rebleeding within 48 h to add up to 9 points and 
prognosticates functional outcome (mRS) at 12  months 
after SAH. The score was developed based on 1526 SAH 
patients with exclusion of the patients in whom care 
was withdrawn (area under the curve [AUC] 89.8%). It 
was validated in a different cohort of 413 patients (AUC 
73.2%). Additional scores for prognostication of cogni-
tive outcome and long-term quality of life at 12 months 
have been developed, such as the FRESH-cog score and 
the FRESH-Quol score. Both models were developed in 
a single-center cohort and have not been externally vali-
dated [26].
The SAHIT score was derived from pooled data of 
10,936 patients from several randomized clinical trials, 
prospective observational studies, and hospital regis-
tries and externally validated in 3355 and 338 patients. 
Outcome was assessed by GOS at 3  months. The final 
model encompasses age, hypertension, WFNS for the 
core model; aneurysm size and location as well as Fisher 
grade for the neuroradiology model; and treatment 
modality for the full model. The addition of these vari-
ables to the core model increased the AUC slightly [24, 
25].
Summary and Gaps
Severity scales such as the original or modified Hunt–
Hess scale, WFNS score, and GCS are still most widely 
used scores to approximate long-term prognosis in daily 
clinical practice and clinical trials. Most of these scores 
were developed in cohorts of < 500 SAH patients with 
single-center or multicenter prospective or single-center 
retrospective study designs.
Newer prognostic models such as FRESH score and 
SAHIT score offer more precise long-term functional 
outcome prediction and are externally validated. Cogni-
tive and psychological outcome measures as well as qual-
ity of life are the most disabling in the SAH population 
and are only accounted for in FRESH-cog and FRESH-
Quol scores which have not been not externally validated.
Several gaps in prognostication in SAH exist: the indi-
vidual patient status prior to the onset of SAH is lacking 
from most models, except for the FRESH-Quol score. The 
development of the prediction models is usually based 
on retrospective analyses of a large patient population, 
and patients with advanced directives against aggressive 
measures as well as mortality associated with withdrawal 
of life support are usually not excluded. All prediction 
scores are mainly based on variables and parameters 
obtained on admission, but in-hospital complications are 
Table 1 FRESH score [26]
FRESH-Cog functional recovery expected after subarachnoid hemorrhage–
cognition at one year after SAH, FRESH-Quol functional recovery expected after 
subarachnoid hemorrhage–quality of life at one year after SAH
FRESH function
Age ≤ 70 > 70
Hunt–Hess scale I–V
Apache II physiologic score Middle arterial pressure Heartrate
Respiratory rate Tempera-
ture
White blood cell count Hematocrit
Sodium Potassium
Aa gradient (if  FiO2 ≥ 50%) 
or  paO2
pH or  HCO3
Creatinine
Rebleeding within 48 h Yes No
FRESH-Cog Years of education up to 
24 years
FRESH-Quol Premorbid glasgow outcome 
scale
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not considered. The optimal time point for assessment 
of predictors of outcome is unknown. There is only one, 
thus far unvalidated model, which includes cognitive and 
psychological outcomes including quality of life, FRESH-
cog, and FRESH-quol. Most clinical trials in SAH do not 
measure these long-term outcomes.
Intracerebral Hemorrhage
Outcome Predictors and Prognostic Models
There are more than 20 published prognostic scores for 
intracerebral hemorrhage (ICH), the majority of which 
were developed using data from single-center cohorts 
[27–29]. The ICH score (i.e., “original ICH score,” or 
oICH score) [30] is the score that has been validated in 
the largest number of independent patient cohorts [31]. 
In its initial publication in 2001, the ICH score was asso-
ciated with 30-day mortality [30]; in 2009, it was vali-
dated for functional outcomes out to 12  months [32]. 
Notable alternatives to the oICH include the ICH-Grad-
ing scale (ICH-GS) [33], which considers supratentorial 
versus infratentorial ICH location; the modified ICH 
score [34] and Essen ICH score [35], which incorporate 
clinical examination findings via the National Institutes 
of Health Stroke scale (NIHSS), as opposed to GCS; the 
ICH-Functional Outcome score (ICH-FOS) [36], which 
incorporates both the GCS and NIHSS; the modified 
Emergency Department ICH (EDICH) score [37, 38], 
which incorporates a patient’s initial International Nor-
malized Ratio (INR) value; and the Functional Outcome 
in Patients with Intracerebral Hemorrhage (FUNC) score 
[39] and Maximally treated ICH (Max-ICH) score [40], 
which were developed in part by using cohorts in which 
patients receiving early limitations of care were removed, 
in an effort to minimize self-fulfilling prophecy effects. 
Whereas the modified ICH score, the ICH-FOS, the 
Essen ICH score, the ICH-GS, and the Max-ICH score 
are associated with in-hospital mortality and long-term 
poor functional outcome (mRS 3–6) up to 12  months. 
The modified EDICH score is associated with 48  h and 
in-hospital mortality, neurological deterioration at 48 h, 
and poor functional outcome at discharge (mRS > 3) [37, 
38]. The FUNC score was designed to predict functional 
independence in surviving patients [39]. Few of these 
modifications of the original ICH score were externally 
validated.
Head-to-head comparisons of ICH prognostic scores 
over the past decade have compared different scores and 
different outcomes, a fact making determination of the 
most robust model a difficult task.
A comparison of eight grading scales in 2011 among 
67 ICH patients in New York suggested that the Essen 
ICH score had the most outstanding discrimination for 
predicting in-hospital mortality, 3-month mortality, 
and 3-month functional outcome, although overall dif-
ferences among the tested scores were minimal [41]. A 
2013 study among 501 patients in Texas concluded that 
the FUNC score and ICH-GS had better discrimination 
for 3-month mortality and functional outcome than the 
oICH score [42].
A 2015 meta-analysis conducted in the UK compared 
12 ICH-GS and concluded that the oICH score and the 
ICH-GS had the greatest amount of worldwide sup-
porting evidence for use in predicting early mortality 
[28]. However, a retrospective analysis of 2556 patients 
from the INTERACT2 trial (a large trial of blood pres-
sure reduction for acute ICH) published that same year 
found that the modified ICH score had better discrimina-
tion for poor 90-day outcome compared to the oICH and 
ICH-GS [43].
Subsequently, a 2016 retrospective analysis of 342 ICH 
patients in Germany suggested an advantage of both the 
oICH score and ICH-GS over the FUNC score in predict-
ing 30-day mortality, based on Pearson correlation [44]. 
A 2018 analysis of 1338 ICH patients in Singapore found 
the ICH-GS slightly more advantageous than the oICH 
score for predicting the same outcome [45].
A 2017 study of 170 ICH patients in Italy concluded 
that the modified EDICH score had better discrimina-
tion than the oICH score, the ICH-GS, and the FUNC 
score with regard to predicting early neurological dete-
rioration, in-hospital mortality, and poor functional out-
come [46]. Finally, a 2017 study comparing 19 prognostic 
scores in 882 Scandinavian ICH patients found that the 
ICH-FOS outperformed all other scores with respect to 
predicting 3-month and 12-month mortality, although 
the NIHSS alone performed just as well as the ICH-FOS 
in predicting in-hospital death [31].
Summary and Gaps
It is currently unclear what the day-to-day clinical impor-
tance should be ascribed to ICH prognostic scores, 
regardless of which one a clinician chooses to use. Some 
have advocated for increased use of prognostic scores to 
help guide clinicians with goals-of-care decision making 
[47]; however, to date, available scoring systems have not 
yet been shown to outperform the early subjective clini-
cal judgment of physician and nurses at academic neu-
roscience centers with regard to predicting functional 
outcomes [48]. The authors of this document caution 
against the use of any ICH prognostic score as the sole 
means for prognosticating outcome for an individual 
patient.
Although prognostic scores typically incorporate clini-
cal variables available upon hospital admission, the time 
window that may truly be best for accurate outcome pre-
diction during an ICH patient’s hospitalization course 
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is currently unclear. As the literature evolves from sim-
ply warning against premature withdrawal of care [49], 
recent studies have suggested that reassessing an ICH 
patient’s clinical exam over a period of 24 h [50] or even 
5 days [51] greatly improves prognostic accuracy. Further 
studies may explore optimal prognostic time periods, 
including when on average ICH patients achieve “prog-
nostic stability.” Also, there is increasing appreciation for 
how patient comorbidities and systemic illnesses associ-
ated with ICH patients during intensive care unit hospi-
talizations (i.e., infections, etc.) may ultimately determine 
patient outcome [52, 53]. There have been some recent 
attempts to include physiologic measures, such as the 
APACHE II score, into ICH prognostication models, 
with varying success (e.g., the Prognosticating Functional 
Outcome after ICH scores) [54–56]. While such attempts 
may make subsequent grading scales more complicated 
to calculate, there is a possibility that further research in 
this area may ultimately help with improving prognostic 
accuracy.
Finally, while the early subjective clinical judgment of 
clinicians at academic neuroscience centers may corre-
late better than oICH and FUNC scores with the func-
tional outcomes of ICH patients, it is not clear whether 
the judgment of non-specialist community clinicians 
would hold an equal advantage in head-to-head testing. 
A study of the accuracy of outcome prediction from non-
neuro-specialist clinicians who nevertheless care for ICH 
patients could potentially reveal an expanded role for the 
judicious use of grading scales and their associated out-
come data in clinical practice.
Ischemic Stroke
Outcome Predictors and Prognostic Models
Model/score-based prognostication after acute ischemic 
stroke (AIS) aims to predict mortality, long-term func-
tional outcome or complete recovery in particular 
[57–60]. Moreover, functional outcome and mortality at 
hospital discharge or after 90  days may be predicted in 
correlation to stroke-specific treatment [61, 62]. Mainly 
based on selected cohorts of AIS patients with hetero-
geneous neurological deficits and medical treatments, 
variables of prediction models were assessed in a defined 
setting and functional outcome was measured at vary-
ing time points after stroke [58]. In addition, treatment 
delays, “the withdrawal of care bias” [63], patient-cen-
tered preferences [64], and even the type of hospital may 
have an impact on treatment decisions [65], which in 
turn affect outcome after AIS. Therefore, generalizabil-
ity of available prognostic models/scores is limited [60]. 
In addition, multi-item models/scores may be regarded 
to be too complex in daily clinical practice, especially if 
neuroimaging or information outside clinical routine has 
to be included [58, 66].
The most relevant ethical question is whether there 
is a threshold of acceptable accuracy of a prognos-
tic model/score, especially regarding decision mak-
ing to withhold potential life-saving treatments after 
AIS [60]. While there are more than a hundred studies 
describing scores to predict functional outcome and/or 
mortality after AIS [59], these scores should not be an 
integral part of clinical routine and were not included 
in AIS guidelines [64, 67].
Every prognostic model has certain strengths and 
weaknesses. Therefore, a quantitative comparison of the 
prognostic accuracy of models is a challenge and prone 
to misinterpretation [57–60]. A recent review focused 
on multi-item scales to predict outcome at 30 days after 
stroke. The eight scales (ASTRAL, iSCORE, iSCORE-r, 
PLAN, SOAR, modified-SOAR, SPI2, and THRIVE) are 
based on clinical data on admission, but do not include 
neuroimaging [60]. External validation using patient-
level data from the Virtual International Stroke Trials 
Archive database demonstrated that scales have dif-
ferent discriminative power. In detail, the Acute Stroke 
Registry and Analysis of Lausanne (ASTRAL) scale had 
a significantly better prognostic discrimination with 
regard to mRS and the best prognostic discrimination 
with regard to the Barthel Index or mortality at 90 days 
after stroke. Interestingly, external validation mostly 
resulted in lower prognostic discrimination compared 
to the baseline publication [59, 60].
Another review focused on AIS prognostic models 
predicting functional outcome at ≥ 90  days based on 
clinical and/or brain imaging using magnetic resonance 
imaging (MRI) or computed tomography (CT) and 
CT perfusion. Overall, seven scales (DRAGON, MRI-
DRAGON, HAT, HIAT, HIAT2, NAV, SAD) including 
neuroimaging data assessed in the acute phase of AIS 
or during follow-up were compared to seven scales 
based on clinical information (ASTRAL, BOAS, iScore, 
NIHSS, sNIHSS-4, SPAN, THRIVE) [58]. Since no rel-
evant differences regarding the discriminative utility of 
the analyzed scales were detected, the authors conclude 
that there is no score “that is the obvious choice for all 
clinical situations” [58].
Based on 10 cohort studies including elderly patients 
with moderate AIS severity, 23 prognostic models for 
complete recovery after AIS were analyzed regarding 
discriminative power and calibration in another recent 
systematic review [57]. Methodological quality of these 
models differed. Compared to a model using the NIHSS 
[68] and stroke volume, multi-predictor models including 
stroke severity, stroke volume, pre-stroke disability, car-
diovascular risk factors, and use of systemic thrombolysis 
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had a similar predictive value. Focusing on a single score, 
functional outcome at 90 days after AIS is highly associ-
ated with stroke severity measured by the NIHSS on hos-
pital admission [64, 69].
Summary and Gaps
In addition to the limited generalizability of published 
prediction models, independent internal and external 
validation of a prognostic model’s calibration and dis-
crimination is a key issue but not available in the majority 
of published models [57–60]. Moreover, there is con-
siderable heterogeneity in validation studies for certain 
scores [59]. Of note, periodical recalibration is needed to 
reflect the impact of novel therapeutic approaches (like 
thrombectomy) that affect outcome after stroke.
Despite methodological improvements in recent years 
[59], even well-validated AIS specific models with good 
prognostic value should not be exclusively used as basis 
for clinical decision making, especially not in emergency 
situations [64, 69]. Based on published prediction mod-
els, multimodal solutions to improve prognostication 
after AIS are needed to reduce the chance of misclassifi-
cation in the individual stroke patient [59, 60].
Traumatic Brain Injury
Outcome Predictors and Prognostic Models
This summary focuses on moderate-severe traumatic 
brain injury (TBI) (post-resuscitation GCS ≤ 12) as 
patients with this severity are commonly admitted to 
neurocritical care units. While summarized under a 
single disease entity, TBI is the most heterogeneous of 
all acute brain injuries in mechanism, pathology, sever-
ity and prognosis [70]. Furthermore, before the common 
data elements [71, 72] were published with the goal to 
standardize data collection in TBI-related research stud-
ies, the high heterogeneity of variables and outcomes 
measured in TBI studies made outcome prediction mod-
eling challenging.
For blunt TBI, two major outcome prediction mod-
els were published in 2008: the International Mission 
for Prognosis and Analysis of Clinical Trials in TBI 
(IMPACT)-model [73] and the Corticosteroid Randomi-
zation after Significant Head Injury (CRASH)-model 
[74]. The IMPACT-model was derived from a large 
TBI cohort (n = 8509) including 11 studies (eight rand-
omized controlled trials and three observational stud-
ies) with GCS ≤ 12 and complete 6-month GOS [73]. 
The model’s outcomes were 6-month mortality and unfa-
vorable outcome (GOS 1–3). Three sub-models were 
created: “core model,” including age, pupillary reactiv-
ity, and motor GCS; “core + CT model,” which addi-
tionally included presence of hypoxia  (O2 saturation 
< 90%) or hypotension (systolic blood pressure < 90 mm 
Hg) in the field or emergency department and Marshall 
CT classification; and “core + CT + lab” model, which 
additionally included hemoglobin and glucose levels 
on admission. The “core” and “core + CT” model were 
externally validated in the CRASH-trial cohort, but the 
“core + CT + lab” model was not due to lack of labora-
tory values from the CRASH-trial. For all three models, 
the discrimination (AUC-ROC) was > 0.8. Calibration, as 
measured by the Hosmer–Lemeshow test, was adequate 
(p value > 0.05). However, the cumulative R2 of the full 
model is 0.35, which means that the IMPACT-model 
only explains about 1/3 of the outcome variability. The 
IMPACT-model is the most widely validated TBI pre-
diction model, including its validation in more contem-
porary cohorts, such as the SYNAPSE-trial dataset [75]. 
The IMPACT-website (www.tbi-impac t.org) contains an 
online IMPACT-model calculator [76]. Disadvantages of 
this calculator are the display of outcome in bar graphs 
instead of IconArrays [77], which are the preferred 
method of graphical risk communication [78]. A second 
disadvantage includes the lack of confidence intervals for 
the estimated outcomes.
The CRASH model was derived in 10,008 patients 
enrolled in the worldwide CRASH-TBI-trial with 
GCS ≤ 14; therefore, the CRASH model is not limited 
to moderate-severe TBI [74]. The model was externally 
validated in the IMPACT-cohort (n = 8509) and predicts 
14-day mortality and 6-month unfavorable outcome 
(GOS 1–3). The CRASH model has the unique feature of 
differentiating outcome by high-income (n = 2482) and 
low-income countries (n = 7526). Compared to high-
income countries, TBI in low-income countries were 
younger, more likely male, recruited later, had less severe 
TBI (higher GCS, better pupillary reactivity), more 
often had an abnormal head CT, had higher mortality 
at 14 days (OR 1.94, 95% CI 1.64–2.3), but there was no 
difference in unfavorable outcome at 6 months [74]. The 
discrimination (AUC-ROC > 0.8) was excellent. The cali-
bration was adequate, except for the low-income country 
models for both outcomes, when including head CT-data 
(Hosmer–Lemeshow p value < 0.05). The CRASH model 
prediction can be accessed via an online calculator [79].
For penetrating TBI (pTBI), only one prediction score 
has been published: the predicting survival after acute 
civilian penetrating brain injuries (SPIN) score [80]. 
This score was derived from 413 patients retrospectively 
retrieved from two US Level-1 trauma centers, which 
poses the largest contemporary cohort of pTBI. The vari-
ables included were motor GCS, pupillary reactivity, self-
inflicted injury, transfer from other hospital, sex, injury 
severity score and admission INR. The AUC-ROC was 
outstanding (0.97); calibration was not reported. While 
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the original SPIN-score publication did not include an 
external validation, in the meantime the authors have 
conducted an external validation in a cohort of 362 
patients from three US Level-1 trauma centers [81]. In 
this external validation, both discrimination and calibra-
tion were excellent (AUC-ROC 0.88; Hosmer–Lemeshow 
p value > 0.05).
Summary and Gaps
Many gaps remain in the outcome prediction after blunt 
and penetrating moderate-severe TBI. One of the major 
gaps arises from the fact that all aforementioned predic-
tion models include only admission variables, disregard-
ing the commonly long hospital course. This is mostly 
due to the lack of standardized hospital course data 
collection in the studies from which these models were 
derived. Additional variables which may improve the 
existing prediction models could include concurring in-
hospital complications, and the trajectory of improve-
ment or worsening after admission. The second gap, 
which, if closed, would have the largest impact on patient 
outcomes, is the standardization and improvement of 
the risk/outcome communication to patient families [32, 
82–84]. This may significantly reduce the influence of 
anecdotal reasoning and bias by healthcare providers or 
families on patients’ healthcare decisions [85–87].
Traumatic Spinal Cord Injury
Outcome Predictors and Prognostic Models
The available literature of the past decade was reviewed 
on prognostic scores and models for outcome prediction 
after traumatic spinal cord injury (SCI). The first clinical 
prediction rule for ambulation outcomes after 12 months 
was derived from a longitudinal cohort study (Euro-
pean Multicenter Study on Human Spinal Cord Injury) 
conducted at 19 centers over a 7-year period. Predictor 
variables were retrieved from standardized neurological 
examinations within 15  days of injury as defined by the 
International Standards for Neurological Classification of 
Spinal Cord Injury in addition to age [88].
A simplified 3-variable model of this prediction rule 
was proposed and tested on the basis of acute phase 
(< 15  days) and outcome (> 12  months) data from the 
Canadian Rick Hansen Spinal Cord Injury Registry [89]. 
Demonstrating similar accuracy, it could potentially 
enhance clinical utility.
Another clinical prediction model for long-term out-
come (at 1  year) after traumatic SCI was based on two 
prospective datasets from the North American Clinical 
Trials Network for SCI and the Surgical Timing in Acute 
Spinal Cord Injury Study [90]. It included both clinical 
and imaging variables obtained in the acute setting (i.e., 
within 72 h of SCI). Data from the US-multicenter Spinal 
Cord Injury Model Systems database were used to com-
pare mathematical models for accurately predicting dif-
ferent levels of independence at 12 months following SCI, 
ambulation status, as well as non-ambulation outcomes 
from rehabilitation admission examinations (i.e., within 
9 weeks of SCI) [88, 91]. All models were based on logis-
tic regression analyses and one employed artificial neu-
ral networks in comparison [91]. Classifications of injury 
severity typically utilize the ASIA impairment scale 
obtained either on admission or within 72  h. Outcome 
assessment at one year included ambulation ability (self-
reported or examined) and composite functional assess-
ments such as the functional independence measure and/
or spinal cord independence measure [92].
Summary and Gaps
In the domain of traumatic SCI, prognostic prediction 
models gain clinical significance through their direct 
impact on decision making and counseling of patients 
and their relatives. Currently, prognostication of out-
comes in SCI is often based on pragmatic single-factor 
designs utilizing for example the clinical examination and 
impairment grading in the acute phase, although later 
time points (e.g., at rehabilitation admission) might be 
of equal importance. Novel diagnostic biomarkers such 
serum proteins are not used, and data from clinical imag-
ing are rarely incorporated. The variation of outcome 
measures can limit the value of prognostication in the 
individual case. In the future, multidimensional outcome 
measures of neurological status, functional performance, 
and psychosocial well-being could bring the complex-
ity of traumatic SCI and post-injury course into the 
limelight.
Improved prognostic modeling could fill the gap in 
order to inform (a) patient and relatives as to the odds 
for specific outcomes, (b) clinicians for individualized 
therapy guidance, and (c) clinical and genetic-molecular 
researchers/statisticians in the development and testing 
of innovative therapeutic measures.
Status Epilepticus
Outcome Predictors and Prognostic Models
Status epilepticus (SE) is characterized by marked het-
erogeneity in both symptoms and underlying etiologies, 
making prediction of prognosis particularly challeng-
ing. In general, the impact of persisting seizures on out-
come diminishes with growing severity of the condition 
that causes them. Although, in a considerable propor-
tion of cases, prognosis of SE is clearly dominated by an 
underlying disease, SE can nonetheless have an impact 
on the outcome either through direct neuronal damage 
or by being a source of complications [93, 94]. Terminat-
ing SE as quickly as possible is, therefore, a well-accepted 
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therapeutic goal in neurocritical care. However, treat-
ment of SE can be hazardous, especially when it is refrac-
tory to anticonvulsants and anesthetics have to be applied 
[95]. By identifying patients with an a priori high chance 
of good outcome, prognostication scores could help rec-
ognize cases with a less favorable risk–benefit ratio.
Prognostication tools providing clinicians with this 
information should be easily applicable and be based on 
readily available patient data, particularly as SE calls for 
timely intervention in most cases. To date, four predic-
tion tools have been created aiming to prognosticate 
in-hospital mortality of SE based on different sets of 
prognosticators. The first ever published score for pre-
diction of outcome in SE, the Status Epilepticus Severity 
score (STESS), meets this requirement, as calculation of 
the score does not need any additional diagnostics [96]. 
In several studies, STESS was repeatedly found a reliable 
predictor of SE outcome. Uncertainty remains, however, 
regarding the optimal STESS threshold that differenti-
ates SE survivors from non-survivors [97]. Recently, an 
increase in prognostic accuracy by adding premorbid 
functional status to STESS was proposed in a modified 
version of STESS [98]. Leitinger and colleagues intro-
duced another score, putting emphasis on detailed dif-
ferentiation of SE etiologies with their impact on SE 
prognosis graded by mortality rates which were taken 
from previous epidemiological studies (Epidemiology-
based Mortality score in SE) [99]. Finally, a group from 
China recently introduced the END-IT score, based, 
among others, on imaging findings and information 
on response to first-line treatment [100]. This score 
was derived from a cohort of young intensive care unit 
patients with a high proportion of encephalitis under-
lying SE. This may limit its applicability to a setting in 
Europe or North America where patients with SE are 
mainly elderly suffering from various etiologies.
Summary and Gaps
Overall, external validation of SE prognosis scores is 
scarce and results of comparisons of score performances 
are controversial [101]. In addition to this shortcoming, 
there are among others two challenges which are not 
addressed by the current scores. Long-term functional 
outcome is not reflected by the current scores which 
mainly focus on in-house mortality and the prediction 
of development and severity of epilepsy after an episode 
of SE is not included in current prognostication tools. In 
summary, the current value of SE outcome scores pos-
sibly lies in assisting clinicians to find optimal treatment 
for their patients in the early stages of a SE episode. Low 
positive predictive values for in-hospital mortality may 
argue against early withdrawal of therapy [101].
Guillain–Barré Syndrome
Outcome Predictors and Prognostic Models
GBS is characterized by a monophasic course that uni-
formly shows improvement over time after reaching its 
nadir. However, it can be acutely fatal from respiratory 
failure and complications of dysautonomia, and recovery 
is often slow and sometimes incomplete [102, 103]. Prog-
nostic studies on GBS have focused on two main end-
points: need for mechanical ventilation and recovery of 
independent ambulation at 6 months.
Respiratory Failure
The Erasmus GBS Respiratory Insufficiency score 
(EGRIS) incorporates the pace of progression of weak-
ness, the presence of facial or bulbar weakness, and the 
severity of the appendicular weakness on admission into 
a simple tool that has been shown to predict accurately 
the need for mechanical ventilation within the first week 
of hospitalization (AUC 0.84 on the derivation cohort 
of 397 patients and AUC 0.82 on a separate validation 
cohort of 191 patients) [104]. The results of pulmonary 
function tests at the bedside (vital capacity < 20  mL/kg, 
maximal inspiratory pressure worse than − 30  cm  H2O, 
maximal expiratory pressure < 40 cm  H2O, or decrease of 
any of these parameters by more than 30%) [105], electro-
physiological findings (demyelinating features) [106], and 
high plasma cortisol level [107] have also been shown to 
be associated with the need for mechanical ventilation, 
but these associations have not been sufficiently validated 
in independent cohorts.
Functional Outcome
Functional outcome as defined by independent ambu-
lation at 6  months can be reliably estimated using 
the Erasmus GBS outcome score (EGOS, Table  2) at 
2 weeks, which was shown to have adequate calibration 
Table 2 The Erasmus GBS respiratory insufficiency score
EGRIS Erasmus GBS respiratory insufficiency score
Factor Categories Score
Days between onset of weakness and hospital 
admission
> 7 days 0
4–7 days 1
≤ 3 days 2
Facial or bulbar weakness at hospital admission Absent 0
Present 1
Medical research counsel sum score at hospital 
admission
60–51 0
50–41 1
40–31 2
30–21 3
≤ 20 4
EGRIS 0–7
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and very good discriminative ability (AUC 0.85) both 
on a derivation cohort (n = 388) and on a separate 
validation cohort (n = 374) [108]. A modified version 
of EGOS (mEGOS, Table  3) that can be applied upon 
hospital admission or at 7 days was also demonstrated 
to have good calibration and discrimination (AUC 
0.75 upon admission and 0.77 at 7  days) [109]. Other 
chemical (e.g., IgG-1 subclass of anti-GM1 antibodies, 
hyponatremia from syndrome of inappropriate secre-
tion of anti-diuretic hormone  (SIADH)), electrophysi-
ological (severe conduction block in common peroneal 
nerve, very reduced amplitude of distal compound 
muscle action potentials (CMAP) or proximal to distal 
CMAP ratio of the peroneal nerve < 55.6%), or demo-
graphic factors (age older than 40 years) may also pre-
dict worse functional recovery [102, 106], but have not 
been incorporated into prediction scores. 
Summary and Gaps
The EGRIS, which may be combined with pulmonary 
function test results, can identify GBS patients who 
will need mechanical ventilation, while the EGOS and 
mEGOS, which may be complemented by electrophysi-
ological data, can discriminate early those patients with 
GBS who will remain non-ambulatory at 6  months. 
These prediction tools are simple, practical, and appli-
cable to all cases of GBS. Yet, there is a lack of infor-
mation on the main determinants of quality of life and 
long-term disability (especially beyond independent 
ambulation) among GBS patients. These two endpoints 
should be addressed in future prospective research by 
incorporating scales of quality of life and emotional 
well-being and extending the follow-up to examine 
persistent residual deficits and reinsertion into the 
workplace.
Cardiac Arrest
Outcome Predictors and Prognostic Models
The earliest prognostic scores for unresponsive patients 
following cardiac arrest came from the sentinel work of 
Levy et  al. from Cornell University in 1985 [110]. Their 
methods were limited by the technologies available at the 
time, and thus consisted only of the clinical examination 
findings during the first 2  weeks post-arrest. However, 
this laid the groundwork for future studies, and several 
of their findings hold true to the modern day, such as 
absence of pupillary and corneal reflexes correlating with 
poor long-term functional outcome and mortality. Few 
studies have replicated or modernized their methods, 
but in 2013 a comprehensive evaluation of 200 coma-
tose cardiac arrest patients was published, incorporating 
the results of ancillary tests, including electrophysiol-
ogy and neuroimaging [111]. Once again, the findings of 
absent pupillary or corneal reflexes strongly correlated 
with poor outcome at 6 months (modified Rankin scale 
4–6) with narrow confidence intervals for false positivity; 
however, previous indicators, such as absent or extensor 
motor findings, or myoclonic status epilepticus (MSE), 
now displayed unacceptably high false positive rates. 
These findings were confirmed by other modern studies.
Four major guidelines have provided prognostic scor-
ing systems: the 2006 American Academy of Neurology 
(AAN) Guidelines [112], the 2013 Swedish Resuscitation 
Council Guidelines [113], the 2014 European Society of 
Intensive Care Medicine (ESICM) Guidelines [114], and 
the 2015 American Heart Association (AHA) Guidelines 
[115].
The 2006 AAN Guidelines were based on studies that 
were largely performed prior to the widespread use of 
therapeutic hypothermia (TH), which subsequently has 
become widely utilized. The AAN Guidelines suggested 
poor outcome defined as death or unconsciousness after 
one month or unconsciousness or severe disability after 
6 months was associated with MSE on day 1, absent N20 
responses on somatosensory evoked potential (SSEP) 
testing on days 1–3, a serum neuron-specific enolase 
(NSE) level of > 33 ng/ml on day 1–3, or absent pupillary 
or corneal reflexes, or absent or extensor motor response 
on day 3 post-arrest. Subsequent studies have described 
good outcomes, mainly assessed at 6  months after car-
diac arrest, even in some patients with MSE and levels 
of NSE > 33  ng/ml, and suggested that prognostication 
is best delayed until the influence of hypothermia can be 
minimized/eliminated.
The Swedish Guidelines were the first to account for 
the influence of hypothermia, advocating waiting 72  h 
after completely rewarming before definitive testing for 
prognosis. These guidelines also separated their recom-
mendations into early and late predictors, both for good 
Table 3 Modified Erasmus GBS outcome score
EGOS Erasmus GBS outcome score
Factor Categories Score
Age at onset (years) ≤ 40 0
41–60 0.5
> 60 1
Diarrhea (within previous 4 weeks) Absent 0
Present 1
Medical research counsel sum score 51–60 0
41–50 3
31–40 6
0–30 9
EGOS 1–12
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and poor functional and cognitive outcome at 6 months, 
although the basis of the recommendations was often 
notably based on weak evidence.
The ESICM guidelines also recommended a wait-
ing period in the setting of TH, as well as the exclusion 
of confounders, particularly residual sedation. Motor 
response was used as a screening tool for potential poor 
functional outcome, but not for definitive prognostica-
tion. Patients with absent pupillary and corneal reflexes, 
or bilaterally absent N20 responses on SSEP, were felt 
“very likely” to have a poor functional outcome assessed 
at 6  months in most studies considered. Subsequently, 
two of four findings (MSE ≤ 48  h post-return of spon-
taneous circulation, “high” NSE levels, non-reactive 
burst-suppression or status epilepticus on electroenceph-
alography (EEG), or “diffuse” anoxic brain injury on brain 
CT/MRI) made poor functional outcome “very likely.” 
They also emphasized the use of multimodal prognosti-
cation whenever possible.
Finally, the AHA Guidelines advocate waiting 72  h 
after return to normothermia, and postulated that nei-
ther absent corneal reflexes nor poor motor responses 
are reliable predictors of poor outcome. MSE was felt still 
to be reliable in combination with other tests, and EEG 
findings of non-reactivity, intractable status epilepticus 
or a persistent burst-suppression pattern were associ-
ated with poor functional outcome (mostly at 6 months). 
SSEP should be performed 24–72  h post-rewarming, 
and imaging, including CT or MRI could also be helpful, 
although without any quantitative guidance for the find-
ings. Finally, NSE and S-100B should not be used alone, 
but “high levels” could support a poor long-term progno-
sis for functional outcome.
Summary and Gaps
Neuroprognostication in cardiac arrest has evolved with 
the introduction of TH, and modern approaches have 
advocated for the use of longer waiting periods and a 
multimodal approach. The clinical exam remains central 
and paramount, but ancillary testing, including electri-
cal, imaging, and chemical, holds promise for future 
studies and incorporation into guidelines. It is worth 
noting that outcomes are typically assessed in cardiac 
arrest using mRS or the Glasgow–Pittsburgh Cerebral 
Performance Category (CPC) scale at 6 months, and the 
definition of a poor versus good outcome varies between 
studies. Typically, a mRS score of 0–3 or a CPC score of 
1–2 is considered good outcome. Furthermore, the tim-
ing of assessment of outcome is variable, including at dis-
charge, 3 months and 6 months, although a few studies 
include assessments up to 12 months after cardiac arrest. 
The guidelines listed above are based on an amalgama-
tion of studies using different methods of assessment of 
outcome, and at different time points. The two largest 
gaps in prognostication after cardiac arrest are 1) lack of 
blinding of the tests being studied, leading to a behavior 
confirmation effect; and 2) premature withdrawal of life-
sustaining therapy, leading to a self-fulfilling prophecy. 
Only when these gaps are eliminated will we have quality 
studies on which to base future recommendations.
Conclusions
Prognostication is inherent in the delivery of neurocriti-
cal care. For essentially every patient admitted to neuro-
critical care, the question arises “how are they going to 
do.” Prognostication is undertaken by clinicians using a 
variety of methods which include informal impressions 
based on experience as well as formal mathematical 
prediction tools derived from analysis of populations of 
patients. Common concerns regarding prognostication 
include accuracy of prognostic models and the informa-
tion upon which prognosis is assessed, how this infor-
mation is delivered to patients and families in order to 
ensure patient-centered shared decision making and limit 
physician bias, and avoidance of the self-fulfilling proph-
ecy of poor outcome if care is limited in a patient that 
might otherwise do well. Although the scope of the joint 
DGNI-NCS prognostication session at the ANIM meet-
ing was purposely limited to prognostic models, all of the 
above concerns were raised across the conditions dis-
cussed, especially regarding conditions such as TBI, ICH, 
and cardiac arrest in which patients may be at high risk 
of early death. Additionally, expanded concerns that are 
often not explicitly addressed regarding long-term prog-
nostication for outcomes of interest such as ambulation, 
return to work, and chronic pain in spinal cord injury 
and GBS were raised as important issues for which there 
is limited information.
Gaps in prognostication were identified for all the con-
ditions presented (Table 4). Most gaps are common to all 
disease states. However, the gaps listed in Table  4 repre-
sent the most salient ones given the available prognostic 
tools. Two common themes that emerged across several 
conditions related to the lack of integration of comor-
bid conditions into most prognostication models and the 
fact that in-hospital events were uncommonly included in 
most models. While some models do include simple meas-
ures as a pre-event functional status, it was commented 
that treating clinicians routinely consider medical comor-
bidities in their assessment of prognosis and this may 
explain why some studies have found clinician assessment 
of prognosis superior to the performance of a specific 
model. Additionally, while some models include sim-
ple information about treatments (e.g., was an aneurysm 
coiled or clipped; was a traumatic intracranial lesion evac-
uated), none included robust information about response 
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to treatment, clinical course overtime, and expanded 
physiology. This information about in-hospital events 
was also considered to include trajectory. The idea that 
the pace of a patient’s early improvement or lack thereof 
as identified by clinical reassessment is an important con-
sideration resonated with numerous presenters and audi-
ence participants. However, clinical reassessment over 
time is not incorporated into essentially any prognostic 
model presented. In addition to known concerns about the 
self-fulfilling prophecy, the absence of information about 
comorbidities, in-hospital care, and trajectory are major 
gaps identified in this analysis and should be addressed in 
future studies. Additionally, prognosis for favorable qual-
ity of life and the potential discordance between this and 
formally assessed functional outcome remain significant 
gaps across all conditions described. Finally, the recogni-
tion of post-intensive care stress disorder in patients and 
even families has not been a focus of prognostication. As 
more attention is paid to shared decision making, quality 
of life, and well-being, this gap deserves to be addressed.
In summary, we present an overview of numerous exist-
ing prognostic models across eight common neurocriti-
cal care conditions. This gap analysis identified several 
specific targetable issues both within individual diseases 
and across the group of conditions discussed. The for-
mat of initial expert presentation with extensive audience 
discussion was felt to be particular effective for this ini-
tial cross-society collaboration regarding this topic. The 
gaps highlighted in the summary for each condition will 
be addressed in a forthcoming formal neuroprognostica-
tion guideline based on a literature search by a medical 
librarian, systematic risk-of-bias assessment with stand-
ardized instruments, and application of GRADE meth-
odology. Furthermore, some of the gaps identified in this 
report need to be addressed by expanded studies of out-
come predictors and prognostic modeling.
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